Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis

Overview

Journal Adv Exp Med Biol

Date 2025 Jan 17

PMID 39821033

Authors

Qianying Zuo

Yibin Kang

Affiliations

Soon will be listed here.

Abstract

Recent evidence has revealed that cancer is not solely driven by genetic abnormalities but also by significant metabolic dysregulation. Cancer cells exhibit altered metabolic demands and rewiring of cellular metabolism to sustain their malignant characteristics. Metabolic reprogramming has emerged as a hallmark of cancer, playing a complex role in breast cancer initiation, progression, and metastasis. The different molecular subtypes of breast cancer exhibit distinct metabolic genotypes and phenotypes, offering opportunities for subtype-specific therapeutic approaches. Cancer-associated metabolic phenotypes encompass dysregulated nutrient uptake, opportunistic nutrient acquisition strategies, altered utilization of glycolysis and TCA cycle intermediates, increased nitrogen demand, metabolite-driven gene regulation, and metabolic interactions with the microenvironment. The tumor microenvironment, consisting of stromal cells, immune cells, blood vessels, and extracellular matrix components, influences metabolic adaptations through modulating nutrient availability, oxygen levels, and signaling pathways. Metastasis, the process of cancer spread, involves intricate steps that present unique metabolic challenges at each stage. Successful metastasis requires cancer cells to navigate varying nutrient and oxygen availability, endure oxidative stress, and adapt their metabolic processes accordingly. The metabolic reprogramming observed in breast cancer is regulated by oncogenes, tumor suppressor genes, and signaling pathways that integrate cellular signaling with metabolic processes. Understanding the metabolic adaptations associated with metastasis holds promise for identifying therapeutic targets to disrupt the metastatic process and improve patient outcomes. This chapter explores the metabolic alterations linked to breast cancer metastasis and highlights the potential for targeted interventions in this context.

References

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

Abu-Elheiga L, Matzuk M, Kordari P, Oh W, Shaikenov T, Gu Z . Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci U S A. 2005; 102(34):12011-6. PMC: 1189351. DOI: 10.1073/pnas.0505714102. View

Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris P . A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150(1):165-78. PMC: 3528019. DOI: 10.1016/j.cell.2012.04.042. View

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

Allen B, Bhatia S, Buatti J, Brandt K, Lindholm K, Button A . Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013; 19(14):3905-13. PMC: 3954599. DOI: 10.1158/1078-0432.CCR-12-0287. View

Andrzejewski S, Klimcakova E, Johnson R, Tabaries S, Annis M, McGuirk S . PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 2017; 26(5):778-787.e5. DOI: 10.1016/j.cmet.2017.09.006. View

Apicella M, Giannoni E, Fiore S, Ferrari K, Fernandez-Perez D, Isella C . Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metab. 2018; 28(6):848-865.e6. DOI: 10.1016/j.cmet.2018.08.006. View

Atlante S, Visintin A, Marini E, Savoia M, Dianzani C, Giorgis M . α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death Dis. 2018; 9(7):756. PMC: 6037705. DOI: 10.1038/s41419-018-0802-8. View

Aykin-Burns N, Ahmad I, Zhu Y, Oberley L, Spitz D . Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J. 2008; 418(1):29-37. PMC: 2678564. DOI: 10.1042/BJ20081258. View

10.

Azimi I, Milevskiy M, Chalmers S, Yapa K, Robitaille M, Henry C . ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes and the Identification of ORAI3 as a Hypoxia Sensitive Gene and a Regulator of Hypoxia Responses. Cancers (Basel). 2019; 11(2). PMC: 6406924. DOI: 10.3390/cancers11020208. View

11.

Baek A, Yu Y, He S, Wardell S, Chang C, Kwon S . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017; 8(1):864. PMC: 5636879. DOI: 10.1038/s41467-017-00910-z. View

12.

Bani I, Williams C, Boulter P, Dickerson J . Plasma lipids and prolactin in patients with breast cancer. Br J Cancer. 1986; 54(3):439-46. PMC: 2001617. DOI: 10.1038/bjc.1986.195. View

13.

Bansal A, Simon M . Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018; 217(7):2291-2298. PMC: 6028537. DOI: 10.1083/jcb.201804161. View

14.

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

15.

Beigneux A, Kosinski C, Gavino B, Horton J, Skarnes W, Young S . ATP-citrate lyase deficiency in the mouse. J Biol Chem. 2003; 279(10):9557-64. PMC: 2888281. DOI: 10.1074/jbc.M310512200. View

16.

Benito A, Polat I, Noe V, Ciudad C, Marin S, Cascante M . Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget. 2018; 8(63):106693-106706. PMC: 5739767. DOI: 10.18632/oncotarget.21601. View

17.

Bertolini I, Perego M, Ghosh J, Kossenkov A, Altieri D . NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment. Oncogene. 2022; 41(17):2520-2525. PMC: 9040905. DOI: 10.1038/s41388-022-02280-3. View

18.

Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4):406-14. DOI: 10.1016/S1470-2045(14)70069-5. View

19.

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

20.

Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A . Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J Pathol. 2014; 234(3):410-22. DOI: 10.1002/path.4416. View